{"url_path":"/sec/lenz/8-k/2026-08-11/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1815776/0001815776-26-000051-index.html","accession_number":"0001815776-26-000051","cik":"0001815776","ticker":"LENZ","issuer_name":"LENZ Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1815776/0001815776-26-000051-index.html","primary_entity_key":"0001815776","primary_entity_name":"LENZ Therapeutics, Inc."},"word_count":136,"has_tables":true,"body_markdown":"Item 2.02 Results of Operations and Financial Condition.\n\nOn August 11, 2026, LENZ Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.\n\nAll of the information furnished in this Item 2.02 and the press release attached hereto as Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing."}